Kleinert S, Krueger K
Medizinische Klinik und Poliklinik II, Rheumatologie/Klinische Immunologie, Universitätsklinikum Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Deutschland.
Z Rheumatol. 2011 Aug;70(6):464-72. doi: 10.1007/s00393-011-0755-0.
Rheumatoid arthritis (RA) is still associated with an increased mortality mainly due to an increase in cardiovascular risk. This increase is not solely explained by traditional cardiovascular risk factors but also by disease characteristics, e.g. inflammation, positive rheumatoid factor and anti-citrullinated peptide antibodies (ACPA). Control of disease activity with disease-modifying drugs (DMARDs) was shown to reduce cardiovascular risk in RA patients. Use of non-steroidal antirheumatic drugs (NSAIDs) and glucocorticoids might be associated with an increased risk. The EULAR recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis have been established. These recommendations are based on national guidelines regarding control of traditional cardiovascular risk factors.
类风湿关节炎（RA）仍与死亡率增加相关，主要原因是心血管风险增加。这种增加不仅由传统心血管危险因素解释，还由疾病特征如炎症、类风湿因子阳性和抗瓜氨酸化肽抗体（ACPA）所致。使用改善病情抗风湿药（DMARDs）控制疾病活动已被证明可降低RA患者的心血管风险。使用非甾体类抗风湿药（NSAIDs）和糖皮质激素可能与风险增加有关。欧洲抗风湿病联盟（EULAR）关于类风湿关节炎和其他形式炎性关节炎患者心血管风险管理的建议已经制定。这些建议基于关于控制传统心血管危险因素的国家指南。
